Volinanserin
Volinanserin is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2A, and 5-hydroxytryptamine receptor 2C.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
7 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | — | — | 4 | — | — | 4 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | 2 | — | — | 2 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | 2 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | — | 1 | — | — | — | 1 |
| Treatment-resistant depressive disorder | D061218 | — | — | — | 1 | — | — | — | 1 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Huntington disease | D006816 | Orphanet_399 | G10 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Volinanserin |
| INN | volinanserin |
| Description | Volinanserin (INN) (developmental code name MDL-100,907) is a highly selective 5-HT2A receptor antagonist that is frequently used in scientific research to investigate the function of the 5-HT2A receptor. It was also tested in clinical trials as a potential antipsychotic, antidepressant, and treatment for insomnia but was never marketed.
|
| Classification | Small molecule |
| Drug class | serotonin 5-HT2 receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC |
Identifiers
| PDB | — |
| CAS-ID | 139290-65-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL74355 |
| ChEBI ID | — |
| PubChem CID | 5311271 |
| DrugBank | — |
| UNII ID | EW71EE171J (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
HTR2B
HTR2B
HTR2A
HTR2A
HTR2C
HTR2C
Organism
Homo sapiens
Gene name
HTR2B
Gene synonyms
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 2B
Protein synonyms
5-HT 2B receptor, 5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled, 5-hydroxytryptamine 2B receptor, Serotonin receptor 2B
Uniprot ID
Mouse ortholog
Htr2b (15559)
5-hydroxytryptamine receptor 2B (Q9QWS2)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 937 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use